Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. We are developing a collection of next-generation immunotherapy agents.
Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy.
At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.
Despite the unprecedented efficacy of existing immunotherapy agents, many patients either fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered novel resistance mechanisms and developed novel agents targeting these mechanisms for improved therapy.
At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.
Employees: 11-50
Total raised: $36.4M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| - | Israel Bio... | ibf.fund |
| - | Myeloma In... | myelomainv... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.12.2022 | Series A | $25M | - |
| 09.03.2022 | - | $5.4M | - |
| 15.07.2020 | - | $6M | aMoon Fund |
Mentions in press and media 8
| Date | Title | Description |
| 25.07.2024 | Nectin Therapeutics Licenses Novel Antibodies to Immunome | JERUSALEM, July 25, 2024 /PRNewswire/ — Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates (ADC) to address tumor resistance, today announced a global, exclusive license agreemen... |
| 31.12.2022 | Препарат израильской компания Nectin Therapeutics может принести иммунотерапию миллионам больных раком | 30 декабря 2022 г. Совершенно новый метод лечения не позволяет опухолевым клеткам «скрываться» и проходит испытания в США. 0 Обсудить 7 просмотров Nectin Therapeutics недавно дала своему первому пациенту дозу своего нового лекарства в рамка... |
| 30.11.2022 | Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies | What You Should Know: The company also announced dosing of the first patient in its Phase 1 clinical trial of NTX1088, Nectin’s first-in-class PVR blocker, in cancer patients with locally advanced and metastatic solid tumors. NTX1088 is a f... |
| 30.11.2022 | Nectin Therapeutics raises $25 million Series A to treat advanced cancer tumors | - |
| 09.03.2022 | Nectin Therapeutics Raises $5.4M in Funding | Nectin Therapeutics Ltd., a Jerusalem, Israel- and Fort lee, NJ-based based biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology treatments, raised $5.4m in funding. Cancer Focu... |
| 07.03.2022 | Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy | - |
| 15.07.2020 | Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics | - |
| - | Nectin Therapeutics | “NectinTX is a biotech company focused on unlocking the power of the immune system by developing a collection of next-gen immunotherapy agents.” |